Physicians recommended chimeric antigen receptor T-cell therapy more frequently than any other regimen for third-line treatment of relapsed or refractory diffuse large B-cell lymphoma, survey results showed. However, nearly one-third of patients for whom CAR-T had been recommended did not receive the treatment, findings from a poll of health care professionals presented at National Comprehensive